Navigation Links
Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film
Date:5/2/2011

JERSEY CITY, N.J., May 2, 2011 /PRNewswire/ -- Aoxing Pharmaceutical (NYSE Amex: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, announced that its operating subsidiary in China, Hebei Aoxing Pharmaceutical Group Company, has been granted a patent by the State Intellectual Property Office of The People's Republic of China for naloxone sublingual film.   The Chinese patent, ZL2005.1.0125279.7, covers a unique sublingual film formulation of naloxone that can be dissolved rapidly under the tongue.  

Naloxone is an opioid receptor antagonist that is used clinically to relieve life-threatening depression of the central nervous system and respiratory system, caused by overdose of morphine and other opioids.  It may also be used as an adjunctive therapy to increase blood pressure in the treatment of septic shocks.  It is most commonly injected intravenously for fastest action.  Oral delivery is used in emergent care due to slow and poor absorption.  However, injection is inconvenient and requires a nurse to administer it.  The sublingual film developed by Aoxing Pharma can be dissolved in under 30 seconds and allows the drug to diffuse into the blood through tissues under the tongue.  The rapid and more efficient absorption of the formulation makes it a convenient alternative to injection.

Mr. Zhenjiang Yue, Chairman and CEO of Aoxing Pharma, commented, "I would like to thank our research and development team for its dedication in driving forward this unique product, now proprietary to Aoxing.  The convenient administration of naloxone could win critical time in emergency and save lives. We look forward to developing this new therapeutic delivery method for this important market."  

About Aoxing P
'/>"/>

SOURCE Aoxing Pharmaceutical Company, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
2. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... BALTIMORE and LONDON , Aug. 28, ... volunteers in the UK, The Gambia and ... of an series of safety trials of potential vaccines aimed at ... the current outbreak in West Africa . ... US National Institutes of Health (NIH) and GlaxoSmithKline, are to be ...
(Date:8/28/2014)... CHARLOTTE, N.C. , Aug. 28, 2014 /PRNewswire/ ... innovation marketplace, today announced a worldwide search for ... of the senior population.  Promising ideas uncovered through ... presented to leading medical device manufacturers and healthcare ... to improve the lives of individuals age 65 ...
(Date:8/28/2014)... 28, 2014 According to a ... Identification (RFID) Market (Tags, Readers, Middleware, Printers and Cabinets) ... Forecast, 2014 - 2020" the global radiofrequency identification (RFID) ... and is expected to grow at a CAGR of ... value of USD 5.3 billion in 2020. ...
Breaking Medicine Technology:Ebola vaccine trials fast-tracked by international consortium 2Ebola vaccine trials fast-tracked by international consortium 3Ebola vaccine trials fast-tracked by international consortium 4Ebola vaccine trials fast-tracked by international consortium 5Ebola vaccine trials fast-tracked by international consortium 6Ebola vaccine trials fast-tracked by international consortium 7Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5
... traits contribute to risk, of skin cancer; findings will ... May 18 In two papers published,today, deCODE scientists ... the company,s recent findings in the genetics of pigmentation,traits ... of these,common variants also confer risk of two types ...
... Annual Meeting Will Further Demonstrate, the Strength ... CAMBRIDGE, Mass., May 16 Millennium Pharmaceuticals,The Takeda Oncology ... are scheduled to be featured at the 2008 American ... May 30 -,June 3, 2008. The data will highlight ...
Cached Medicine Technology:deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 2deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 3deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8
(Date:8/28/2014)... 28, 2014 Home Care Assistance ... for seniors, is proud to welcome Carrie Rose as ... Home Care Assistance, Carrie worked as a caregiver in ... Certified Nursing Assistant in skilled nursing facilities for several ... a trainer with the State of Arizona in the ...
(Date:8/28/2014)... have been adopted by most health agencies to deal ... unnecessary, and may heighten panic and fear among the ... published in The Lancet , and written by ... in Spain, and colleagues. , Ebola virus is ... faeces and other secretions, both direct and indirect, from ...
(Date:8/28/2014)... become increasingly about datahow to gather it, organize ... databases to analyze and share data lies at ... collection, classification, storage, and analysis of biochemical and ... and methods used in bioinformatics have been instrumental ... genetics and genomics. But, in the plant sciences, ...
(Date:8/28/2014)... Worth, FL (PRWEB) August 28, 2014 Following ... on July 21, the FDA issued a warning ... the word about this harmful substance that is readily available ... , In May, high school senior Logan Stiner died from ... investigation of the substance, leading the FDA to issue a ...
(Date:8/28/2014)... researchers place glue directly on the nerve stumps, but ... and allows glue to easily invade the nerve ends. ... to insert the nerve ends into the conduit because ... Xiangdang Liang and co-workers from the General Hospital of ... technique and defined the best parameters for its use ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance Expands Staff to Meet Growing Demand for In-Home Care Services in Scottsdale 2Health News:Home Care Assistance Expands Staff to Meet Growing Demand for In-Home Care Services in Scottsdale 3Health News:The Lancet: Respiratory infection controls being used for ebola patients are unnecessary and may contribute to public panic 2Health News:Together, humans and computers can figure out the plant world 2Health News:Together, humans and computers can figure out the plant world 3Health News:FDA Issues Safety Advisory for Caffeine Powders 2
... Presents Study at International Society of Cellular Therapy ... Cells for Possible Utilization in TransplantationOLDSMAR, Fla., May ... announced results of a new study showing that ... cells from umbilical cord blood expands the number ...
... N.Y., May 5 Nutrition 21, Inc. (Nasdaq: ... help consumers manage blood sugar levels, improve cardiovascular health, enhance ... - prior to the opening of the market - on ... year 2009, ended March 31, 2009. The Company has scheduled ...
... 5 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex" or the ... independent American,provider of Western healthcare products and services ... the Company is scheduled to participate in the,Oppenheimer ... 19-21, 2009, at,300 Madison Avenue in New York ...
... Assists Physicians In Identifying Recurrence Risk and the Need ... Clarient, Inc. (Nasdaq: CLRT ... resource for pathologists, oncologists and the pharmaceutical industry, today ... test that helps physicians identify the probability of a ...
... It,s official...Curamin is the natural products industry,s Best ... number-one pain-relieving product, is slated to receive a ... magazine in its upcoming June issue. The ... based on a nationwide survey of health food ...
... medical supplies on a regular basis can save even more with ... many struggle with rising medical costs, the MSD Club membership will ... incontinence and other disposable medical supplies. , ... (PRWEB) ...
Cached Medicine News:Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 2Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 3Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 4Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 5Health News:Nutrition 21 to Report Third Quarter Fiscal Year 2009 Financial Results on Tuesday, May 12, 2009 2Health News:Chindex International, Inc. Announces May Conference Participation 2Health News:Clarient Launches New Breast Cancer Test 2Health News:Clarient Launches New Breast Cancer Test 3Health News:Clarient Launches New Breast Cancer Test 4Health News:Clarient Launches New Breast Cancer Test 5Health News:Clarient Launches New Breast Cancer Test 6Health News:Curamin Voted Best New Natural Remedy in the Country 2Health News:TheMedicalSupplyDepot.com Announces New Discount Medical Supplies MSD Club 2
Used for the introduction of catheters, balloons and other vascular devices....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Sheath Introducer featuring patented SLIX Valve, rotating collar, kink-resistant cannula and atraumatic tip transitions....
The TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in native coronary arteries = 2.5 to = 3....
Medicine Products: